In This Section

CICR Steering Committee

Philip Jones, PhD
Chairperson

Philip Jones, PhD

(2020-2021)

Vice President, Therapeutics Discovery, and Head of Drug Discovery
UT MD Anderson Cancer Center
Houston, Texas

Joachim Rudolph, PhD
CICR Chairperson-elect

Joachim Rudolph, PhD

(2020-2021)

Principal Scientist, Discovery Chemistry
Genentech, Inc.
South San Francisco, California

Andrew J. Phillips, PhD
Past Chairperson

Andrew J. Phillips, PhD

(2020-2021)

Former President and Chief Scientific Officer
C4 Therapeutics
Cambridge, Massachusetts

James E. Audia, PhD

James E. Audia, PhD

(2019-2021)

Visiting Scholar, Northwestern University
Head of Medicinal Chemistry and Senior Advisor, Karuna Therapeutics
Entrepreneur-in Residence, Third Rock Ventures
Evanston, Illlinois

Ivan Cornella-Taracido, PhD

Ivan Cornella-Taracido, PhD

(2019-2021)

Vice President, Proteomics and Chemical Biology
Cedilla Therapeutics
Cambridge, Massachusetts

Laura Akullian D’Agostino, PhD

Laura Akullian D’Agostino, PhD

(2020-2022)

Director, Drug Discovery
Celgene Corporation
Cambridge, Massachusetts

Adrian L. Gill, PhD

Adrian L. Gill, PhD

(2020-2022)

Vice President, Medicinal Chemistry
Revolution Medicines
Redwood City, California

Christopher Nasveschuk, PhD

Christopher Nasveschuk, PhD

(2020-2022)

Vice President, Chemistry
C4 Therapeutics
Watertown, Massachusetts

Chudi O. Ndubaku, PhD

Chudi O. Ndubaku, PhD

(2019-2021)

Vice President, Drug Discovery
ORIC Pharmaceuticals
South San Francisco, California

Zoran Rankovic, PhD

Zoran Rankovic, PhD

(2020-2022)

Director, CBT Chemistry Centers
St. Jude Children’s Research Hospital
Memphis, Tennessee

Xiaojing (Gina) Wang

Xiaojing (Gina) Wang

(2019-2021)

Principal Scientist and Project Team Lead
Genentech, Inc.
South San Francisco, California

Iain D.G. Watson, PhD
Non-Voting Member

Iain D.G. Watson, PhD

(2020)

Senior Scientist, Drug Discovery
Ontario Institute for Cancer Research (OICR)
Toronto, Ontario, Canada